New Delhi, May 20 -- Speaking on the results, Dr. Sharvil Patel, Managing Director Zydus Lifesciences said, "We are happy to conclude FY 2025 on a strong note, with all our businesses surpassing our growth expectations. The commercial success of our extensive product portfolio combined with operating leverage has significantly bolstered profitability and financial health. We made meaningful progress in our differentiated pipeline and added new capabilities to ensure sustainable growth. We look forward to continued execution success and deepening strategic partnerships to drive long term growth. Our commitment to maintaining the highest quality standards across our operations remains unwavering."

Published by HT Digital Content Services w...